Latest News

If you are wondering whether Urban Edge Properties at around US$19.98 is still offering value or starting to look fully priced, you are asking the right question. The stock shows returns of 4.2% over 7 days, 4.6% over 30 days, 4.6% year to date, 4.3% over 1 year, 39.5% over 3 years and 59.3% over 5 years, which gives useful context before weighing up what you are paying today. Recent market attention has focused on Urban Edge Properties as a US real estate name, with investors weighing up...

Kuaishou Technology ( HKG:1024 ) saw a double-digit share price rise of over 10% in the past couple of months on the...

Electrical Industries Company ( TADAWUL:1303 ) shareholders have had their patience rewarded with a 27% share price...

As Gulf markets show resilience with gains ahead of earnings and amid geopolitical tensions, investors are increasingly turning their attention to dividend stocks for stable returns. In this environment, selecting stocks with strong fundamentals and attractive yields can be a prudent strategy for those looking to capitalize on the region's economic growth.

Avidia Bancorp (AVBC) has wrapped up FY 2025 with fourth quarter revenue of US$26.1 million, net income of US$5.3 million and basic EPS of US$0.29, set against trailing twelve month revenue of US$82.1 million and a TTM net loss of US$3.3 million or EPS of US$0.18. The company has seen revenue move from US$88.5 million in FY 2024 to US$82.1 million on a trailing basis, while earnings have shifted from a profit of US$11.5 million over FY 2024 to a TTM loss of US$3.3 million. This leaves...

In late January and early February 2026, Daiichi Sankyo and AstraZeneca reported that the U.S. FDA accepted and granted Priority Review to their supplemental Biologics License Application for DATROWAY in unresectable or metastatic triple negative breast cancer, based on phase 3 data showing a clinically meaningful overall survival benefit versus chemotherapy. This Priority Review, supported by robust response rates and participation in the FDA’s Project Orbis program, highlights how DATROWAY...

PepsiCo (PEP) has put fresh numbers on the board for FY 2025, reporting Q3 revenue of US$23.9b and basic EPS of US$1.90, alongside trailing 12 month revenue of US$92.4b and EPS of US$5.27. These figures sit against a reported net margin of 7.8% compared with 10.2% a year earlier. Over recent quarters the company has seen revenue range from US$17.9b in Q1 2025 to US$27.8b in Q4 2024, while basic EPS moved between US$0.92 and US$2.24. This gives investors a clear look at how headline growth has...

In late January 2026, MINISO Group Holding outlined an accelerated global growth roadmap at its Global Partner Conference in Guangzhou, focusing on immersive store upgrades, proprietary IP development, and expanded international reach, while also reporting a strong fiscal third quarter 2025 that exceeded its own revenue guidance and marked a milestone of more than 8,000 stores worldwide. An interesting development is the launch of the MINISO IP Genius Program, which aims to build...

Analyst reaction to Phase 1 trial progress Piper Sandler and Barclays recently updated their views on CytomX Therapeutics (CTMX) after promising Phase 1 data for varsetatug maseatecan in metastatic colorectal cancer, highlighting renewed investor attention ahead of further clinical readouts. See our latest analysis for CytomX Therapeutics. The share price, which last closed at US$6.07, has seen a 42.82% year to date share price return and a very large 1 year total shareholder return,...

Docebo (TSX:DCBO) has launched a substantial issuer bid to repurchase and cancel up to 2,940,000 shares. The offer is part of a CA$60m buyback program and represents over 10% of the company’s issued share capital. The move signals how management is choosing to deploy capital and could affect ownership concentration and per share metrics. Docebo is coming to this buyback after a difficult stretch for the share price, with the stock at CA$26.0 and showing a 56.4% decline over the past year...

BeOne Medicines (NasdaqGS:ONC) received its first regulatory clearance for BCL2 inhibitor sonrotoclax, supporting clinical development in chronic lymphocytic leukemia. The company extended its collaboration with InSysBio to apply translational modeling for dose selection and cytokine release syndrome risk management in future studies. BeOne Medicines focuses on oncology drug development. Sonrotoclax is now moving into a new regulatory phase that puts more attention on its BCL2 approach in...

AMETEK (AME) has just posted another set of quarterly numbers, with Q3 FY 2025 revenue at US$1,892.6 million and basic EPS of US$1.61 setting the tone for the year so far. The company has seen revenue move from US$1,708.6 million in Q3 FY 2024 to US$1,892.6 million in Q3 FY 2025. Over the same quarters, basic EPS went from US$1.47 to US$1.61, supported by trailing twelve month EPS of US$6.36 on revenue of about US$7.2 billion. Taken together with a trailing net margin of 20.5% versus 19.3% a...

Pfizer (PFE) has just posted its FY 2025 third quarter numbers, reporting revenue of US$16.7b and basic EPS of US$0.62, with trailing twelve month EPS at US$1.73. The company has seen revenue move from US$17.8b in Q4 2024 to US$13.7b in Q1 2025 and US$14.7b in Q2 2025, while quarterly EPS shifted from US$0.07 to US$0.52 and US$0.51 over the same stretch. This feeds into a 15.6% net profit margin over the last 12 months compared with 7.0% a year earlier, giving investors a clearer view of how...

EXL, a global data and AI company, was recently named a Leader for Payer Digital Transformation Services in the ISG Provider Lens Healthcare Digital Services – US 2025 study, marking its fourth consecutive recognition in this category. This repeated Leader status underscores EXL’s combination of artificial intelligence, data, and cloud capabilities with deep healthcare payer expertise to modernize complex operational systems. Next, we’ll examine how this continued leadership in payer digital...

Community Financial System, Inc. has reported past fourth-quarter 2025 results, with net interest income rising to US$133.43 million and net income reaching US$54.42 million, alongside basic and diluted earnings per share from continuing operations of US$1.03. The period also saw net charge-offs fall to US$2,328,000 and the board affirm a quarterly cash dividend of US$0.47 per share, underscoring an emphasis on both credit quality and shareholder returns. We’ll now examine how the...

If you are wondering whether Northrop Grumman at around US$704.98 is offering fair value or stretching expectations, this article is designed to help you make sense of the numbers. The stock has returned 3.9% over the last 7 days, 20.4% over the past month and year to date, 48.7% over 1 year, 63.9% over 3 years, and 152.0% over 5 years. These figures naturally raise questions about what is already priced in and where the risk might sit for new investors. Recent coverage around Northrop...

Investors may be wondering whether Napco Security Technologies, at around US$43.74, is still a sensible entry or addition to a portfolio, or if most of the value story is already reflected in the price. The stock has moved sharply at times, with returns of 13.7% over the last 7 days, 5.7% over the last 30 days, 5.7% year to date, 68.3% over the last year, 27.3% over 3 years, and 198.1% over 5 years. This naturally raises questions about risk and reward at today's level. Recent attention on...

The Australian market is facing a cautious start to the day following the Reserve Bank's recent rate hike, with ASX 200 futures indicating a potential dip amid broader global economic concerns. In this climate of uncertainty, investors often turn their attention to smaller or newer companies that can offer unique opportunities for growth and value. Although the term "penny stocks" might seem outdated, these stocks still represent an intriguing segment of the market where financial strength...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

It is hard to get excited after looking at Paramount Speciality Forgings' (NSE:PSFL) recent performance, when its stock...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...